Avontec
Founded Year
2001Stage
Series B | DeadTotal Raised
$23.21MLast Raised
$17.83MAbout Avontec
Developer of nucleic acid-based anti-inflammatory drugs for the treatment of asthma, psoriasis, and rheumatoid arthritis. The company develops drugs based on oligonucleotides which act as decoys for disease-related transcription factors. It also develops programs in respiratory disease, skin disease, transplant rejection, cardiovascular disease, and autoimmune disease. [Keyword: deoxyribonucleic acid (DNA)]
Missing: Avontec's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Avontec's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Avontec Patents
Avontec has filed 3 patents.
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
9/12/2003 | 8/17/2010 | Molecular biology, Genetics, DNA, Nucleic acids, Biotechnology | Grant |
Application Date | 9/12/2003 |
|---|---|
Grant Date | 8/17/2010 |
Title | |
Related Topics | Molecular biology, Genetics, DNA, Nucleic acids, Biotechnology |
Status | Grant |
Avontec Frequently Asked Questions (FAQ)
When was Avontec founded?
Avontec was founded in 2001.
Where is Avontec's headquarters?
Avontec's headquarters is located at Fraunhoferstrasse 15, Martinsried.
What is Avontec's latest funding round?
Avontec's latest funding round is Series B.
How much did Avontec raise?
Avontec raised a total of $23.21M.
Who are the investors of Avontec?
Investors of Avontec include Mediport, Deutsche Venture Capital, InnoCap, BioMedPartners and TBG.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.